ProQR Therapeutics Management
Management criteria checks 4/4
ProQR Therapeutics' CEO is Daniel de Boer, appointed in Feb 2012, has a tenure of 12.75 years. total yearly compensation is €2.44M, comprised of 21.5% salary and 78.5% bonuses, including company stock and options. directly owns 0.68% of the company’s shares, worth $2.55M. The average tenure of the management team and the board of directors is 4.8 years and 6.2 years respectively.
Key information
Daniel de Boer
Chief executive officer
€2.4m
Total compensation
| CEO salary percentage | 21.5% |
| CEO tenure | 12.8yrs |
| CEO ownership | 0.7% |
| Management average tenure | 4.8yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump
Oct 23
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected
Jul 15Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher
May 29Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01
ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -€24m |
| Jun 30 2024 | n/a | n/a | -€22m |
| Mar 31 2024 | n/a | n/a | -€27m |
| Dec 31 2023 | €2m | €524k | -€28m |
| Sep 30 2023 | n/a | n/a | -€36m |
| Jun 30 2023 | n/a | n/a | -€54m |
| Mar 31 2023 | n/a | n/a | -€59m |
| Dec 31 2022 | €2m | €504k | -€64m |
| Sep 30 2022 | n/a | n/a | -€69m |
| Jun 30 2022 | n/a | n/a | -€61m |
| Mar 31 2022 | n/a | n/a | -€63m |
| Dec 31 2021 | €2m | €449k | -€61m |
| Sep 30 2021 | n/a | n/a | -€57m |
| Jun 30 2021 | n/a | n/a | -€55m |
| Mar 31 2021 | n/a | n/a | -€43m |
| Dec 31 2020 | €3m | €449k | -€47m |
| Sep 30 2020 | n/a | n/a | -€52m |
| Jun 30 2020 | n/a | n/a | -€51m |
| Mar 31 2020 | n/a | n/a | -€58m |
| Dec 31 2019 | €2m | €449k | -€56m |
| Sep 30 2019 | n/a | n/a | -€51m |
| Jun 30 2019 | n/a | n/a | -€45m |
| Mar 31 2019 | n/a | n/a | -€40m |
| Dec 31 2018 | €1m | €445k | -€37m |
| Sep 30 2018 | n/a | n/a | -€35m |
| Jun 30 2018 | n/a | n/a | -€40m |
| Mar 31 2018 | n/a | n/a | -€44m |
| Dec 31 2017 | €1m | €353k | -€44m |
Compensation vs Market: Daniel's total compensation ($USD2.54M) is about average for companies of similar size in the US market ($USD2.24M).
Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.
CEO
Daniel de Boer (41 yo)
12.8yrs
Tenure
€2,439,000
Compensation
Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He serves as Member of Strategic Advisory Board at Hybridize...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.8yrs | €2.44m | 0.68% $ 2.5m | |
| Founder & Independent Member of Supervisory Board | no data | €150.00k | 0.41% $ 1.5m | |
| Chief Corporate Development Officer | 2.4yrs | €1.31m | 0.45% $ 1.7m | |
| Co-Founder | 12.8yrs | €34.00k | no data | |
| Chief Financial Officer | 2yrs | no data | no data | |
| Chief People & Operations Officer | 4.8yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Junior Financial Controller | no data | no data | no data |
4.8yrs
Average Tenure
54yo
Average Age
Experienced Management: PRQR's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Independent Member of Supervisory Board | 10.8yrs | €150.00k | 0.41% $ 1.5m | |
| Independent Member of Supervisory Board | 10.2yrs | €126.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 7.4yrs | no data | no data | |
| Supervisory Board Member | 1.5yrs | €271.00k | 0.026% $ 95.7k | |
| Chairman of the Board of Directors & Chairman of Scientific Advisory Board | 4.3yrs | €132.00k | 0.060% $ 222.2k | |
| Member of the Board of Directors | 5.8yrs | €127.00k | 0% $ 0 | |
| Supervisory Board Member & Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member Scientific Advisory Board | 6.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.5yrs | no data | no data | |
| Member of the Board of Directors | 1.8yrs | €84.00k | 0% $ 0 |
6.2yrs
Average Tenure
63.5yo
Average Age
Experienced Board: PRQR's board of directors are considered experienced (6.2 years average tenure).